Detalhe da pesquisa
1.
MacroH2A histone variants maintain nuclear organization and heterochromatin architecture.
J Cell Sci
; 130(9): 1570-1582, 2017 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28283545
2.
A Cbx8-containing polycomb complex facilitates the transition to gene activation during ES cell differentiation.
PLoS Genet
; 10(12): e1004851, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25500566
3.
A cellular model reflecting the phenotypic heterogeneity of mutant HRAS driven squamous cell carcinoma.
Int J Cancer
; 139(5): 1106-16, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27074337
4.
MacroH2As regulate enhancer-promoter contacts affecting enhancer activity and sensitivity to inflammatory cytokines.
Cell Rep
; 39(12): 110988, 2022 06 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35732123
5.
Evolution of a histone variant involved in compartmental regulation of NAD metabolism.
Nat Struct Mol Biol
; 28(12): 1009-1019, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34887560
6.
The Histone Variant MacroH2A1 Regulates Key Genes for Myogenic Cell Fusion in a Splice-Isoform Dependent Manner.
Cells
; 9(5)2020 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32365743
7.
Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes.
Oncotarget
; 8(70): 115002-115017, 2017 Dec 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29383137
8.
MacroH2A1.1 regulates mitochondrial respiration by limiting nuclear NAD+ consumption.
Nat Struct Mol Biol
; 24(11): 902-910, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28991266
9.
Downregulation of the Deiminase PADI2 Is an Early Event in Colorectal Carcinogenesis and Indicates Poor Prognosis.
Mol Cancer Res
; 14(9): 841-8, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27280713
10.
MacroH2A1 regulates the balance between self-renewal and differentiation commitment in embryonic and adult stem cells.
Mol Cell Biol
; 32(8): 1442-52, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22331466
11.
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.
Cancer Res
; 68(22): 9221-30, 2008 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19010894
12.
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Cancer Res
; 68(19): 8022-30, 2008 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18829560